Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.65 |
| ▸ | CA1 | P00915 | 6/20 | 0.65 |
| ▸ | CA2 | P00918 | 6/20 | 0.65 |
| ▸ | CA7 | P43166 | 6/20 | 0.65 |
| ▸ | CA9 | Q16790 | 6/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | XDH | P47989 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | CA6 | P23280 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403210 | 0.89 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1483249 | 0.85 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL330670 | 0.85 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL136284 | 0.85 | CA1 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31258831 | 0.85 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL820141 | 0.85 | KDM4E (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29699657 | 0.85 | KDM4E (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4424415 | 0.84 | CA1 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL293611 | 0.83 | KDM4E (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL293610 | 0.83 | KDM4E (0.53) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312504-A1 | VOLATILE COMPOSITION DISPENSER FOR COMPOSITIONS COMPRISING A META-(C1-C4 ALKOXY) SALICYLALDEHYDE | THE PROCTER & GAMBLE COMPANY | 2025-10-09 | — | — | US | disclosed |
| EP-4573087-A1 | USE OF (ISOINDOLIN-2-YL)(4-HYDROXY-3-(ISOINDOLINE-2-CARBONYL)PHENYL)METHANONES IN THE TREATMENT OF TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PROTEIN 1 DYSFUNCTION | University of Notre Dame du Lac (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-118255698-A | Sulfonamide compound and preparation method and application thereof | 海南大学 | 2024-06-28 | — | — | CN | disclosed |
| US-20240199997-A1 | COMPOSITIONS COMPRISING A META-(C1-C4 ALKOXY) SALICYLALDEHYDE | PROCTER & GAMBLE COMPANY, THE | 2024-06-20 | — | — | US | disclosed |
| WO-2024044553-A1 | USE OF (ISOINDOLIN-2-YL)(4-HYDROXY-3-(ISOINDOLINE-2-CARBONYL)PHENYL)METHANONES IN THE TREATMENT OF TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PROTEIN 1 DYSFUNCTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044553-A1 | USE OF (ISOINDOLIN-2-YL)(4-HYDROXY-3-(ISOINDOLINE-2-CARBONYL)PHENYL)METHANONES IN THE TREATMENT OF TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PROTEIN 1 DYSFUNCTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-2483254-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2014-08-13 | — | — | EP | disclosed |
| US-8778939-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| EP-2483254-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184553-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-07-19 | — | — | US | disclosed |
| WO-2011038572-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-04-07 | — | — | WO | disclosed |
| US-7358249-B2 | Heterocyclic compounds having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2008-04-15 | — | — | US | disclosed |
| US-5017569-A | Cephalosporin derivatives | ICI PHARMA (FR) | 1991-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184553-A1 | NOVEL COMPOUNDS | LRRK2, PARK7, PINK1 | CA12 4873/4885CA1 4717/4885CA2 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.